| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Toxoplasma | 65 | 2024 | 120 | 10.840 |
Why?
|
| Toxoplasmosis | 34 | 2024 | 70 | 7.520 |
Why?
|
| Toxoplasmosis, Congenital | 26 | 2024 | 49 | 4.780 |
Why?
|
| Toxoplasmosis, Animal | 14 | 2019 | 20 | 2.410 |
Why?
|
| Antiprotozoal Agents | 15 | 2013 | 31 | 2.210 |
Why?
|
| Antibodies, Protozoan | 16 | 2024 | 46 | 2.170 |
Why?
|
| Enoyl-(Acyl-Carrier-Protein) Reductase (NADH) | 11 | 2013 | 12 | 1.680 |
Why?
|
| Protozoan Vaccines | 5 | 2016 | 11 | 1.670 |
Why?
|
| Protozoan Proteins | 12 | 2018 | 77 | 1.670 |
Why?
|
| Toxoplasmosis, Ocular | 10 | 2018 | 17 | 1.450 |
Why?
|
| Triclosan | 9 | 2013 | 10 | 1.270 |
Why?
|
| Immunoglobulin M | 9 | 2024 | 165 | 1.210 |
Why?
|
| Epitopes, T-Lymphocyte | 5 | 2016 | 96 | 1.200 |
Why?
|
| Coccidiostats | 4 | 2013 | 4 | 1.180 |
Why?
|
| Pregnancy Complications, Parasitic | 8 | 2024 | 16 | 1.030 |
Why?
|
| Plasmodium falciparum | 11 | 2020 | 55 | 1.010 |
Why?
|
| Antigens, Protozoan | 8 | 2020 | 22 | 0.830 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2020 | 668 | 0.770 |
Why?
|
| Spiramycin | 2 | 2021 | 2 | 0.750 |
Why?
|
| Pregnancy | 19 | 2024 | 3240 | 0.740 |
Why?
|
| Neglected Diseases | 1 | 2021 | 1 | 0.730 |
Why?
|
| Immunoglobulin G | 10 | 2024 | 481 | 0.710 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 56 | 0.710 |
Why?
|
| Animals | 52 | 2020 | 28945 | 0.700 |
Why?
|
| Mice | 30 | 2020 | 12562 | 0.670 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2021 | 127 | 0.660 |
Why?
|
| Parasites | 1 | 2020 | 11 | 0.650 |
Why?
|
| Interferon-gamma | 6 | 2014 | 467 | 0.600 |
Why?
|
| Hydrocephalus | 2 | 2015 | 108 | 0.580 |
Why?
|
| Female | 49 | 2024 | 50063 | 0.580 |
Why?
|
| Genotype | 7 | 2018 | 1882 | 0.570 |
Why?
|
| Mice, Transgenic | 10 | 2020 | 1645 | 0.560 |
Why?
|
| Oocysts | 4 | 2017 | 8 | 0.550 |
Why?
|
| HLA-A Antigens | 3 | 2016 | 40 | 0.540 |
Why?
|
| Cytokines | 4 | 2018 | 872 | 0.530 |
Why?
|
| Cat Diseases | 1 | 2017 | 20 | 0.520 |
Why?
|
| Pets | 1 | 2017 | 10 | 0.520 |
Why?
|
| Dog Diseases | 1 | 2017 | 37 | 0.520 |
Why?
|
| HLA-B7 Antigen | 3 | 2020 | 7 | 0.510 |
Why?
|
| Adjuvants, Immunologic | 4 | 2020 | 174 | 0.500 |
Why?
|
| Triazines | 2 | 2008 | 55 | 0.490 |
Why?
|
| Quinolones | 1 | 2016 | 57 | 0.480 |
Why?
|
| Toxoplasmosis, Cerebral | 3 | 2009 | 6 | 0.480 |
Why?
|
| Antiparasitic Agents | 3 | 2013 | 9 | 0.480 |
Why?
|
| Humans | 70 | 2024 | 96127 | 0.470 |
Why?
|
| Oxidoreductases | 4 | 2004 | 115 | 0.470 |
Why?
|
| Antimalarials | 5 | 2012 | 21 | 0.470 |
Why?
|
| Encephalitis | 2 | 2008 | 101 | 0.460 |
Why?
|
| Infant, Newborn | 11 | 2024 | 2614 | 0.460 |
Why?
|
| Drug Discovery | 1 | 2016 | 118 | 0.460 |
Why?
|
| Family Health | 1 | 2015 | 159 | 0.460 |
Why?
|
| Models, Molecular | 10 | 2018 | 1375 | 0.450 |
Why?
|
| Nervous System Diseases | 1 | 2016 | 172 | 0.440 |
Why?
|
| Cells, Cultured | 10 | 2020 | 2943 | 0.440 |
Why?
|
| Sulfadiazine | 7 | 2008 | 24 | 0.440 |
Why?
|
| Drug Design | 4 | 2013 | 133 | 0.440 |
Why?
|
| Fathers | 1 | 2015 | 82 | 0.440 |
Why?
|
| Cluster Analysis | 1 | 2015 | 392 | 0.430 |
Why?
|
| Benzamides | 2 | 2012 | 248 | 0.420 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 257 | 0.420 |
Why?
|
| Spiro Compounds | 1 | 2013 | 30 | 0.410 |
Why?
|
| Mice, Inbred C57BL | 11 | 2016 | 3490 | 0.410 |
Why?
|
| Nanoparticles | 2 | 2020 | 197 | 0.400 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2017 | 380 | 0.400 |
Why?
|
| Genes, MHC Class I | 4 | 2010 | 48 | 0.390 |
Why?
|
| Salicylanilides | 1 | 2012 | 1 | 0.390 |
Why?
|
| Proctocolectomy, Restorative | 2 | 2006 | 115 | 0.390 |
Why?
|
| Morpholinos | 1 | 2012 | 13 | 0.380 |
Why?
|
| Promoter Regions, Genetic | 2 | 2018 | 992 | 0.380 |
Why?
|
| Fibroblasts | 7 | 2013 | 781 | 0.370 |
Why?
|
| Infant | 12 | 2021 | 3363 | 0.370 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2018 | 2473 | 0.370 |
Why?
|
| Chorioretinitis | 3 | 2008 | 9 | 0.370 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2012 | 52 | 0.360 |
Why?
|
| Indoles | 1 | 2013 | 317 | 0.360 |
Why?
|
| Mice, Inbred BALB C | 7 | 2014 | 1125 | 0.360 |
Why?
|
| Parasitology | 1 | 2011 | 2 | 0.360 |
Why?
|
| Peptides | 2 | 2014 | 672 | 0.360 |
Why?
|
| Vaccines, Subunit | 3 | 2020 | 55 | 0.360 |
Why?
|
| Point-of-Care Testing | 3 | 2022 | 28 | 0.360 |
Why?
|
| H-2 Antigens | 3 | 2010 | 57 | 0.350 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2018 | 2494 | 0.350 |
Why?
|
| Phenyl Ethers | 1 | 2010 | 13 | 0.340 |
Why?
|
| Ribosomal Proteins | 1 | 2010 | 45 | 0.330 |
Why?
|
| Enzyme Inhibitors | 7 | 2013 | 657 | 0.320 |
Why?
|
| Structure-Activity Relationship | 6 | 2013 | 436 | 0.320 |
Why?
|
| Carrier Proteins | 2 | 2013 | 684 | 0.320 |
Why?
|
| Disease Models, Animal | 7 | 2016 | 2551 | 0.320 |
Why?
|
| Pyridines | 2 | 2010 | 319 | 0.320 |
Why?
|
| Nitriles | 1 | 2010 | 157 | 0.320 |
Why?
|
| Genetic Therapy | 1 | 2012 | 382 | 0.310 |
Why?
|
| Prevalence | 5 | 2021 | 1349 | 0.300 |
Why?
|
| Cats | 4 | 2017 | 306 | 0.300 |
Why?
|
| Amino Acid Sequence | 8 | 2011 | 2092 | 0.300 |
Why?
|
| Prenatal Diagnosis | 3 | 2024 | 110 | 0.300 |
Why?
|
| Cell Cycle | 1 | 2010 | 518 | 0.290 |
Why?
|
| Cell Proliferation | 3 | 2013 | 1761 | 0.290 |
Why?
|
| Child, Preschool | 10 | 2016 | 3974 | 0.290 |
Why?
|
| Nerve Degeneration | 1 | 2008 | 84 | 0.290 |
Why?
|
| Apicomplexa | 2 | 2012 | 5 | 0.280 |
Why?
|
| Sensitivity and Specificity | 5 | 2024 | 2040 | 0.280 |
Why?
|
| Infectious Disease Transmission, Vertical | 5 | 2010 | 45 | 0.270 |
Why?
|
| Cryptosporidium parvum | 2 | 2005 | 4 | 0.270 |
Why?
|
| Molecular Sequence Data | 9 | 2011 | 3041 | 0.270 |
Why?
|
| Child | 13 | 2016 | 7626 | 0.270 |
Why?
|
| HIV Infections | 1 | 2016 | 974 | 0.250 |
Why?
|
| Agglutination Tests | 2 | 2017 | 12 | 0.250 |
Why?
|
| Shikimic Acid | 2 | 2006 | 2 | 0.250 |
Why?
|
| Mass Screening | 1 | 2011 | 710 | 0.250 |
Why?
|
| Genes, MHC Class II | 3 | 2002 | 31 | 0.240 |
Why?
|
| Adolescent | 11 | 2024 | 9896 | 0.240 |
Why?
|
| Drug Hypersensitivity | 1 | 2006 | 40 | 0.240 |
Why?
|
| Molecular Structure | 5 | 2013 | 310 | 0.240 |
Why?
|
| Brain | 6 | 2011 | 2482 | 0.240 |
Why?
|
| Colombia | 3 | 2024 | 18 | 0.230 |
Why?
|
| Serologic Tests | 2 | 2018 | 43 | 0.230 |
Why?
|
| Pyrimethamine | 7 | 2008 | 21 | 0.230 |
Why?
|
| Colonic Pouches | 1 | 2006 | 97 | 0.230 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2013 | 153 | 0.230 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 3 | 2012 | 34 | 0.220 |
Why?
|
| Male | 23 | 2023 | 45870 | 0.220 |
Why?
|
| Anastomosis, Surgical | 1 | 2006 | 283 | 0.220 |
Why?
|
| Epitopes | 2 | 2020 | 258 | 0.220 |
Why?
|
| Cohort Studies | 6 | 2015 | 3107 | 0.220 |
Why?
|
| Incidence | 5 | 2016 | 1715 | 0.210 |
Why?
|
| False Positive Reactions | 1 | 2024 | 222 | 0.210 |
Why?
|
| Drug Resistance | 2 | 2016 | 237 | 0.210 |
Why?
|
| Monocytes | 3 | 2016 | 231 | 0.210 |
Why?
|
| United States | 9 | 2018 | 7767 | 0.200 |
Why?
|
| Chromatography, Affinity | 1 | 2023 | 84 | 0.200 |
Why?
|
| Alleles | 3 | 2018 | 1157 | 0.200 |
Why?
|
| Mitochondria | 2 | 2005 | 623 | 0.200 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2020 | 488 | 0.190 |
Why?
|
| Glycine | 1 | 2002 | 96 | 0.180 |
Why?
|
| Pupil Disorders | 1 | 2021 | 3 | 0.180 |
Why?
|
| Seroepidemiologic Studies | 2 | 2021 | 57 | 0.180 |
Why?
|
| Megalencephaly | 1 | 2021 | 21 | 0.170 |
Why?
|
| Pouchitis | 1 | 2001 | 57 | 0.170 |
Why?
|
| In Vitro Techniques | 2 | 2013 | 1010 | 0.170 |
Why?
|
| Morbidity | 2 | 2016 | 160 | 0.160 |
Why?
|
| Adult | 17 | 2024 | 28718 | 0.160 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2000 | 96 | 0.160 |
Why?
|
| Nitric Oxide | 2 | 2010 | 281 | 0.160 |
Why?
|
| Sequence Alignment | 4 | 2007 | 360 | 0.160 |
Why?
|
| Neurons | 1 | 2008 | 1653 | 0.160 |
Why?
|
| Virulence | 3 | 2015 | 279 | 0.160 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2000 | 126 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 569 | 0.150 |
Why?
|
| Nitric Oxide Synthase | 1 | 2000 | 123 | 0.150 |
Why?
|
| Gene Frequency | 2 | 2018 | 703 | 0.150 |
Why?
|
| HLA-DQ Antigens | 1 | 1999 | 52 | 0.150 |
Why?
|
| One Health | 1 | 2019 | 2 | 0.150 |
Why?
|
| Disease Susceptibility | 2 | 2018 | 220 | 0.150 |
Why?
|
| Immunoassay | 2 | 2017 | 100 | 0.150 |
Why?
|
| Cell Line | 7 | 2016 | 2533 | 0.150 |
Why?
|
| Vaccination | 2 | 2011 | 311 | 0.150 |
Why?
|
| Collagen Type II | 2 | 2009 | 16 | 0.150 |
Why?
|
| Vaccines | 1 | 2000 | 84 | 0.140 |
Why?
|
| Sarcoma | 1 | 2000 | 225 | 0.140 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2013 | 65 | 0.140 |
Why?
|
| Risk Factors | 6 | 2021 | 5960 | 0.140 |
Why?
|
| Crystallography, X-Ray | 4 | 2018 | 527 | 0.140 |
Why?
|
| Radiotherapy | 1 | 2000 | 328 | 0.140 |
Why?
|
| Enzymes | 1 | 2018 | 47 | 0.140 |
Why?
|
| Spleen | 2 | 2014 | 439 | 0.140 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2009 | 142 | 0.140 |
Why?
|
| Drug Delivery Systems | 2 | 2013 | 198 | 0.140 |
Why?
|
| Gene Knockdown Techniques | 3 | 2018 | 257 | 0.140 |
Why?
|
| Bone Neoplasms | 1 | 2000 | 320 | 0.140 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2010 | 320 | 0.140 |
Why?
|
| Recurrence | 5 | 2011 | 1218 | 0.140 |
Why?
|
| Panama | 1 | 2017 | 7 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2013 | 1973 | 0.130 |
Why?
|
| Age Factors | 3 | 2008 | 1963 | 0.130 |
Why?
|
| Lymphadenitis | 1 | 1996 | 7 | 0.130 |
Why?
|
| Chicago | 2 | 2015 | 1503 | 0.130 |
Why?
|
| Fertilization | 1 | 1996 | 41 | 0.130 |
Why?
|
| Mice, Inbred C3H | 3 | 2002 | 372 | 0.130 |
Why?
|
| Chickens | 1 | 2017 | 212 | 0.130 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1958 | 0.130 |
Why?
|
| HLA-A2 Antigen | 2 | 2020 | 32 | 0.130 |
Why?
|
| Parasite Egg Count | 1 | 2016 | 7 | 0.130 |
Why?
|
| Cytochromes b | 1 | 2016 | 12 | 0.130 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 168 | 0.120 |
Why?
|
| Cross-Priming | 1 | 2016 | 54 | 0.120 |
Why?
|
| Young Adult | 5 | 2024 | 7025 | 0.120 |
Why?
|
| Chronic Disease | 3 | 2008 | 983 | 0.120 |
Why?
|
| Animal Welfare | 1 | 2017 | 59 | 0.120 |
Why?
|
| International Classification of Diseases | 1 | 2016 | 67 | 0.120 |
Why?
|
| Drug Administration Schedule | 2 | 2009 | 873 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 847 | 0.120 |
Why?
|
| Dogs | 1 | 2017 | 719 | 0.120 |
Why?
|
| Serogroup | 1 | 2015 | 12 | 0.120 |
Why?
|
| Haplotypes | 1 | 2018 | 650 | 0.120 |
Why?
|
| Morocco | 3 | 2021 | 17 | 0.120 |
Why?
|
| Urban Population | 1 | 2017 | 240 | 0.120 |
Why?
|
| Luminescent Proteins | 2 | 2013 | 145 | 0.120 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 321 | 0.120 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2008 | 422 | 0.110 |
Why?
|
| Immunologic Memory | 1 | 2016 | 188 | 0.110 |
Why?
|
| Bacterial Translocation | 1 | 2015 | 26 | 0.110 |
Why?
|
| Salmonella Infections, Animal | 1 | 2015 | 11 | 0.110 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2015 | 40 | 0.110 |
Why?
|
| Salmonella typhimurium | 1 | 2015 | 32 | 0.110 |
Why?
|
| Crohn Disease | 2 | 2001 | 806 | 0.110 |
Why?
|
| Intestinal Mucosa | 2 | 2015 | 825 | 0.110 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2016 | 209 | 0.110 |
Why?
|
| Parasitic Sensitivity Tests | 3 | 2013 | 5 | 0.110 |
Why?
|
| Feces | 1 | 2016 | 360 | 0.110 |
Why?
|
| Drug Therapy, Combination | 5 | 2008 | 813 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 111 | 0.110 |
Why?
|
| Genes, Protozoan | 2 | 2004 | 9 | 0.110 |
Why?
|
| Arachidonate 12-Lipoxygenase | 1 | 2014 | 26 | 0.100 |
Why?
|
| Endoscopy | 1 | 1997 | 374 | 0.100 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 2860 | 0.100 |
Why?
|
| Mitochondrial Proteins | 2 | 2005 | 129 | 0.100 |
Why?
|
| Visual Acuity | 4 | 2008 | 209 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2013 | 112 | 0.100 |
Why?
|
| Adenosine Triphosphatases | 1 | 2013 | 156 | 0.100 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2012 | 7 | 0.100 |
Why?
|
| Lymphocytes | 1 | 2015 | 489 | 0.100 |
Why?
|
| Binding Sites | 2 | 2013 | 1167 | 0.090 |
Why?
|
| Zebrafish | 1 | 2015 | 342 | 0.090 |
Why?
|
| Comorbidity | 1 | 2016 | 1011 | 0.090 |
Why?
|
| Blotting, Western | 2 | 2011 | 798 | 0.090 |
Why?
|
| Trypanocidal Agents | 1 | 2012 | 2 | 0.090 |
Why?
|
| Serotyping | 1 | 2012 | 28 | 0.090 |
Why?
|
| Leishmania donovani | 1 | 2012 | 2 | 0.090 |
Why?
|
| Trypanosoma | 1 | 2012 | 3 | 0.090 |
Why?
|
| Luciferases | 1 | 2012 | 130 | 0.090 |
Why?
|
| Imides | 1 | 2012 | 26 | 0.090 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2012 | 9 | 0.090 |
Why?
|
| Immunity, Innate | 4 | 2015 | 464 | 0.090 |
Why?
|
| HLA-A1 Antigen | 1 | 2011 | 1 | 0.090 |
Why?
|
| Secretory Pathway | 1 | 2012 | 23 | 0.090 |
Why?
|
| Gene Transfer Techniques | 1 | 2012 | 156 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 4 | 2017 | 930 | 0.090 |
Why?
|
| Lymphocyte Activation | 3 | 2020 | 810 | 0.090 |
Why?
|
| Food Contamination | 1 | 2011 | 35 | 0.090 |
Why?
|
| Bacterial Proteins | 3 | 2013 | 922 | 0.090 |
Why?
|
| Gene Expression Regulation | 4 | 2010 | 2059 | 0.090 |
Why?
|
| Organelles | 1 | 2012 | 58 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2009 | 1981 | 0.090 |
Why?
|
| Aged | 5 | 2023 | 20964 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2012 | 2092 | 0.090 |
Why?
|
| Myosin Subfragments | 1 | 2011 | 6 | 0.090 |
Why?
|
| Models, Economic | 1 | 2011 | 62 | 0.090 |
Why?
|
| Myosin Light Chains | 1 | 2011 | 29 | 0.090 |
Why?
|
| Enzyme Activation | 2 | 2013 | 692 | 0.090 |
Why?
|
| Protein Binding | 2 | 2016 | 1561 | 0.090 |
Why?
|
| Middle Aged | 6 | 2023 | 28363 | 0.090 |
Why?
|
| Ileum | 1 | 2011 | 169 | 0.090 |
Why?
|
| Tetracyclines | 1 | 2010 | 5 | 0.090 |
Why?
|
| Cataract | 2 | 2011 | 87 | 0.080 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 2010 | 9 | 0.080 |
Why?
|
| Epithelial Cells | 1 | 2015 | 710 | 0.080 |
Why?
|
| Nitrobenzenes | 1 | 2010 | 12 | 0.080 |
Why?
|
| Eating | 1 | 2011 | 165 | 0.080 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2011 | 151 | 0.080 |
Why?
|
| Retinal Diseases | 2 | 2011 | 84 | 0.080 |
Why?
|
| Microsomes, Liver | 1 | 2010 | 49 | 0.080 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1990 | 97 | 0.080 |
Why?
|
| Small Molecule Libraries | 1 | 2011 | 70 | 0.080 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2010 | 16 | 0.080 |
Why?
|
| Immunization | 1 | 2010 | 165 | 0.080 |
Why?
|
| Protein Transport | 1 | 2012 | 439 | 0.080 |
Why?
|
| Vision Disorders | 2 | 2011 | 72 | 0.080 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 28 | 0.080 |
Why?
|
| Aminopeptidases | 1 | 2010 | 14 | 0.080 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2010 | 40 | 0.080 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 326 | 0.080 |
Why?
|
| Protein Biosynthesis | 1 | 2012 | 399 | 0.080 |
Why?
|
| Lipopeptides | 1 | 2010 | 20 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 204 | 0.080 |
Why?
|
| Heat-Shock Proteins | 1 | 2010 | 184 | 0.080 |
Why?
|
| RNA, Catalytic | 1 | 2010 | 134 | 0.080 |
Why?
|
| Phylogeny | 2 | 2006 | 1275 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2010 | 212 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2008 | 9173 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 307 | 0.070 |
Why?
|
| Lateral Ventricles | 1 | 2008 | 12 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 898 | 0.070 |
Why?
|
| Retinal Hemorrhage | 1 | 2008 | 9 | 0.070 |
Why?
|
| Choroidal Neovascularization | 1 | 2008 | 23 | 0.070 |
Why?
|
| Atrophy | 1 | 2008 | 132 | 0.070 |
Why?
|
| Galactolipids | 1 | 2008 | 2 | 0.070 |
Why?
|
| Intracellular Space | 1 | 2008 | 38 | 0.070 |
Why?
|
| Neonatal Screening | 1 | 2009 | 67 | 0.070 |
Why?
|
| Cricetulus | 1 | 2008 | 132 | 0.070 |
Why?
|
| CHO Cells | 1 | 2008 | 196 | 0.070 |
Why?
|
| NAD | 4 | 2013 | 99 | 0.070 |
Why?
|
| Microglia | 1 | 2008 | 124 | 0.070 |
Why?
|
| Models, Genetic | 2 | 2010 | 983 | 0.070 |
Why?
|
| Protein Conformation | 3 | 2018 | 935 | 0.070 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 1034 | 0.070 |
Why?
|
| Cricetinae | 1 | 2008 | 544 | 0.070 |
Why?
|
| Epigenesis, Genetic | 2 | 2009 | 554 | 0.060 |
Why?
|
| Protein Structure, Secondary | 1 | 2008 | 342 | 0.060 |
Why?
|
| Plant Proteins | 2 | 2007 | 143 | 0.060 |
Why?
|
| Prenatal Care | 2 | 2024 | 84 | 0.060 |
Why?
|
| Macrophages | 1 | 2010 | 626 | 0.060 |
Why?
|
| Ontario | 1 | 2006 | 56 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 829 | 0.060 |
Why?
|
| Databases as Topic | 1 | 2006 | 96 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 458 | 0.060 |
Why?
|
| Lipids | 1 | 2007 | 285 | 0.060 |
Why?
|
| Eye Diseases | 2 | 2011 | 59 | 0.060 |
Why?
|
| Anal Canal | 1 | 2006 | 92 | 0.060 |
Why?
|
| Folic Acid Antagonists | 1 | 2005 | 17 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 1 | 2008 | 515 | 0.060 |
Why?
|
| Behavior, Animal | 1 | 2008 | 394 | 0.060 |
Why?
|
| Eosinophilia | 1 | 2006 | 89 | 0.060 |
Why?
|
| Genome, Protozoan | 1 | 2005 | 11 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2008 | 1267 | 0.060 |
Why?
|
| Flow Cytometry | 2 | 2010 | 727 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2006 | 599 | 0.060 |
Why?
|
| Species Specificity | 2 | 2007 | 707 | 0.060 |
Why?
|
| Rats | 2 | 2008 | 4154 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2011 | 1316 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 1534 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2023 | 4671 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2006 | 244 | 0.050 |
Why?
|
| Salicylamides | 1 | 2004 | 2 | 0.050 |
Why?
|
| Oxyquinoline | 1 | 2004 | 4 | 0.050 |
Why?
|
| Permeability | 2 | 2015 | 144 | 0.050 |
Why?
|
| DNA, Protozoan | 1 | 2003 | 15 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2006 | 819 | 0.050 |
Why?
|
| Leucovorin | 3 | 2008 | 227 | 0.050 |
Why?
|
| Mice, Knockout | 3 | 2015 | 2163 | 0.050 |
Why?
|
| Reoperation | 1 | 2006 | 707 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2006 | 10286 | 0.050 |
Why?
|
| Histocompatibility Antigen H-2D | 1 | 2002 | 4 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2008 | 3651 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2010 | 1730 | 0.050 |
Why?
|
| Length of Stay | 1 | 2006 | 833 | 0.050 |
Why?
|
| Phosphorus-Oxygen Lyases | 1 | 2002 | 1 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 1431 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2002 | 218 | 0.050 |
Why?
|
| Time Factors | 3 | 2018 | 5585 | 0.050 |
Why?
|
| Crosses, Genetic | 1 | 2002 | 171 | 0.040 |
Why?
|
| Biomarkers | 1 | 2008 | 1933 | 0.040 |
Why?
|
| Genetic Variation | 2 | 2014 | 1423 | 0.040 |
Why?
|
| Twins, Dizygotic | 1 | 2021 | 42 | 0.040 |
Why?
|
| RNA Interference | 2 | 2014 | 385 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2001 | 64 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2001 | 115 | 0.040 |
Why?
|
| Cognition | 1 | 2006 | 635 | 0.040 |
Why?
|
| Delayed Diagnosis | 1 | 2021 | 41 | 0.040 |
Why?
|
| HLA-A11 Antigen | 1 | 2020 | 2 | 0.040 |
Why?
|
| Genome | 1 | 2004 | 407 | 0.040 |
Why?
|
| Multigene Family | 1 | 2001 | 213 | 0.040 |
Why?
|
| CD8 Antigens | 2 | 2010 | 84 | 0.040 |
Why?
|
| Incidental Findings | 1 | 2021 | 99 | 0.040 |
Why?
|
| Algorithms | 1 | 2009 | 2014 | 0.040 |
Why?
|
| Colonic Polyps | 1 | 2001 | 137 | 0.040 |
Why?
|
| Parasitemia | 1 | 2000 | 7 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2006 | 891 | 0.040 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2001 | 161 | 0.040 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2000 | 45 | 0.040 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 1999 | 24 | 0.040 |
Why?
|
| Herbicides | 1 | 1999 | 36 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2000 | 89 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 270 | 0.040 |
Why?
|
| Propionates | 1 | 1999 | 36 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2010 | 3586 | 0.040 |
Why?
|
| Vitreous Body | 2 | 2011 | 54 | 0.040 |
Why?
|
| Protein Engineering | 1 | 2020 | 150 | 0.040 |
Why?
|
| Homozygote | 1 | 1999 | 208 | 0.040 |
Why?
|
| Animals, Wild | 1 | 2019 | 52 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 1874 | 0.040 |
Why?
|
| France | 1 | 2018 | 54 | 0.040 |
Why?
|
| Sex Factors | 1 | 2002 | 1133 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2002 | 1546 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2001 | 465 | 0.040 |
Why?
|
| Actuarial Analysis | 1 | 1997 | 66 | 0.030 |
Why?
|
| Abortion, Spontaneous | 1 | 2018 | 74 | 0.030 |
Why?
|
| Biopsy | 1 | 2001 | 1220 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 155 | 0.030 |
Why?
|
| Massachusetts | 1 | 2017 | 35 | 0.030 |
Why?
|
| Ohio | 1 | 2017 | 42 | 0.030 |
Why?
|
| Farms | 1 | 2017 | 9 | 0.030 |
Why?
|
| Maryland | 1 | 2017 | 46 | 0.030 |
Why?
|
| Public Health | 1 | 2018 | 155 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2017 | 147 | 0.030 |
Why?
|
| Biological Assay | 1 | 2017 | 84 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 1996 | 23 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 64 | 0.030 |
Why?
|
| Immunocompetence | 1 | 1996 | 27 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 157 | 0.030 |
Why?
|
| Developing Countries | 1 | 2017 | 91 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2017 | 479 | 0.030 |
Why?
|
| Infant, Newborn, Diseases | 1 | 1996 | 118 | 0.030 |
Why?
|
| Radiography | 1 | 1997 | 826 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 1619 | 0.030 |
Why?
|
| Mutation | 2 | 2002 | 4374 | 0.030 |
Why?
|
| Ecosystem | 1 | 2019 | 394 | 0.030 |
Why?
|
| Mothers | 1 | 1996 | 155 | 0.030 |
Why?
|
| Integrin alpha Chains | 1 | 2015 | 18 | 0.030 |
Why?
|
| Occludin | 1 | 2015 | 66 | 0.030 |
Why?
|
| Transplantation Chimera | 1 | 2015 | 84 | 0.030 |
Why?
|
| X-Ray Diffraction | 2 | 2006 | 131 | 0.030 |
Why?
|
| Mice, Inbred A | 1 | 1994 | 23 | 0.030 |
Why?
|
| HLA-B27 Antigen | 1 | 1994 | 8 | 0.030 |
Why?
|
| Caspase 1 | 1 | 2014 | 20 | 0.030 |
Why?
|
| HLA-C Antigens | 1 | 1994 | 18 | 0.030 |
Why?
|
| HLA-D Antigens | 1 | 1994 | 21 | 0.030 |
Why?
|
| Crystallization | 2 | 2006 | 216 | 0.030 |
Why?
|
| Colitis, Ulcerative | 1 | 2001 | 801 | 0.030 |
Why?
|
| Arachidonic Acid | 1 | 2014 | 65 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2008 | 1175 | 0.030 |
Why?
|
| Protein Unfolding | 1 | 2013 | 12 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2015 | 294 | 0.030 |
Why?
|
| Heart | 1 | 2017 | 592 | 0.030 |
Why?
|
| Linkage Disequilibrium | 2 | 2008 | 481 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2013 | 111 | 0.030 |
Why?
|
| Temperature | 1 | 2015 | 426 | 0.030 |
Why?
|
| Molecular Docking Simulation | 1 | 2013 | 58 | 0.030 |
Why?
|
| Plasmids | 1 | 2014 | 291 | 0.030 |
Why?
|
| Caco-2 Cells | 1 | 2013 | 125 | 0.020 |
Why?
|
| High-Throughput Screening Assays | 1 | 2013 | 65 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2015 | 482 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2013 | 217 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 1996 | 565 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 241 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2013 | 411 | 0.020 |
Why?
|
| Prognosis | 1 | 2000 | 4033 | 0.020 |
Why?
|
| Trypanosoma brucei rhodesiense | 1 | 2012 | 1 | 0.020 |
Why?
|
| Trypanosoma cruzi | 1 | 2012 | 8 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 567 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2012 | 171 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 2011 | 91 | 0.020 |
Why?
|
| Uveitis, Anterior | 1 | 2011 | 5 | 0.020 |
Why?
|
| Choroiditis | 1 | 2011 | 8 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2011 | 79 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2011 | 27 | 0.020 |
Why?
|
| Swine Diseases | 1 | 2011 | 15 | 0.020 |
Why?
|
| Optic Nerve Diseases | 1 | 2011 | 16 | 0.020 |
Why?
|
| North America | 1 | 2011 | 199 | 0.020 |
Why?
|
| Meat | 1 | 2011 | 27 | 0.020 |
Why?
|
| Kinetics | 1 | 2013 | 1562 | 0.020 |
Why?
|
| NLR Proteins | 1 | 2010 | 3 | 0.020 |
Why?
|
| Brazil | 1 | 2011 | 82 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 363 | 0.020 |
Why?
|
| Cicatrix | 1 | 2011 | 72 | 0.020 |
Why?
|
| Receptors, Purinergic P2X7 | 1 | 2010 | 9 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 205 | 0.020 |
Why?
|
| Cell Death | 1 | 2010 | 265 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2000 | 7232 | 0.020 |
Why?
|
| Swine | 1 | 2011 | 618 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2010 | 195 | 0.020 |
Why?
|
| Ranibizumab | 1 | 2008 | 19 | 0.020 |
Why?
|
| Genomic Imprinting | 1 | 2008 | 32 | 0.020 |
Why?
|
| Fluorescein Angiography | 1 | 2008 | 83 | 0.020 |
Why?
|
| Injections | 1 | 2008 | 126 | 0.020 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2008 | 29 | 0.020 |
Why?
|
| Spinacia oleracea | 1 | 2008 | 16 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2007 | 25 | 0.020 |
Why?
|
| Chloroplasts | 1 | 2008 | 69 | 0.020 |
Why?
|
| Tomography, Optical Coherence | 1 | 2008 | 131 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2012 | 771 | 0.020 |
Why?
|
| Eye | 1 | 2008 | 112 | 0.020 |
Why?
|
| Cataract Extraction | 1 | 2007 | 32 | 0.020 |
Why?
|
| Apoenzymes | 1 | 2007 | 8 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2008 | 206 | 0.020 |
Why?
|
| Amino Acids, Aromatic | 1 | 2006 | 3 | 0.020 |
Why?
|
| Hydro-Lyases | 1 | 2006 | 7 | 0.020 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2006 | 17 | 0.020 |
Why?
|
| Rabbits | 1 | 2008 | 639 | 0.020 |
Why?
|
| Transferases | 1 | 2006 | 23 | 0.020 |
Why?
|
| Lyases | 1 | 2006 | 11 | 0.020 |
Why?
|
| Wechsler Scales | 1 | 2006 | 21 | 0.020 |
Why?
|
| Prokaryotic Cells | 1 | 2006 | 15 | 0.020 |
Why?
|
| Vision, Monocular | 1 | 2006 | 15 | 0.020 |
Why?
|
| Intelligence Tests | 1 | 2006 | 39 | 0.020 |
Why?
|
| Multienzyme Complexes | 1 | 2006 | 63 | 0.020 |
Why?
|
| Macula Lutea | 1 | 2006 | 17 | 0.020 |
Why?
|
| Language Tests | 1 | 2006 | 39 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2011 | 1158 | 0.020 |
Why?
|
| Vision, Binocular | 1 | 2006 | 21 | 0.020 |
Why?
|
| Gene Fusion | 1 | 2006 | 40 | 0.020 |
Why?
|
| Eukaryotic Cells | 1 | 2006 | 44 | 0.020 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2006 | 42 | 0.020 |
Why?
|
| Eukaryota | 1 | 2006 | 47 | 0.020 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2006 | 81 | 0.020 |
Why?
|
| Fungi | 1 | 2006 | 67 | 0.020 |
Why?
|
| Solvents | 1 | 2006 | 91 | 0.020 |
Why?
|
| Antibodies | 1 | 2008 | 357 | 0.020 |
Why?
|
| Plants | 1 | 2006 | 127 | 0.010 |
Why?
|
| Symbiosis | 1 | 2006 | 134 | 0.010 |
Why?
|
| Water | 1 | 2007 | 307 | 0.010 |
Why?
|
| Pattern Recognition, Visual | 1 | 2006 | 162 | 0.010 |
Why?
|
| Inflammation | 1 | 2011 | 1068 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2008 | 696 | 0.010 |
Why?
|
| Actins | 1 | 2008 | 473 | 0.010 |
Why?
|
| Apoptosis | 1 | 2010 | 1763 | 0.010 |
Why?
|
| Maltose-Binding Proteins | 1 | 2003 | 31 | 0.010 |
Why?
|
| Genes, Switch | 1 | 2002 | 8 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 648 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 1020 | 0.010 |
Why?
|
| Bacteria | 1 | 2006 | 517 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 2002 | 152 | 0.010 |
Why?
|
| Host-Parasite Interactions | 1 | 2002 | 33 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 2002 | 107 | 0.010 |
Why?
|
| Gestational Age | 1 | 2003 | 343 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2003 | 564 | 0.010 |
Why?
|
| DNA Primers | 1 | 1999 | 548 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2001 | 1083 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 1192 | 0.010 |
Why?
|
| Base Sequence | 1 | 1999 | 2344 | 0.010 |
Why?
|